×

Innoviva Number of Employees 2010-2024 | INVA

Innoviva number of employees from 2010 to 2024. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis
Innoviva Annual Employee Count
2024 127
2023 112
2022 101
2021 5
2020 5
2019 6
2018 6
2017 12
2016 14
2015 13
2014 10
2013 241
2012 226
2011 222
2010 193
2009 194
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.132B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $835.717B 67.80
Novo Nordisk (NVO) Denmark $406.526B 27.53
Johnson & Johnson (JNJ) United States $394.223B 16.39
AbbVie (ABBV) United States $360.274B 20.17
Roche Holding AG (RHHBY) Switzerland $264.748B 0.00
Merck (MRK) United States $230.880B 11.95
Novartis AG (NVS) Switzerland $223.246B 13.98
Pfizer (PFE) United States $151.025B 8.57
Sanofi (SNY) $136.409B 12.92
Bayer (BAYRY) Germany $23.028B 3.69